Since the publication of the guidelines for the assessment and management of non alcoholic
fatty liver disease (NAFLD) by the Asia–Pacific Working Party on NAFLD in 2007, 1 our …

Introduction Semaglutide, a peptidic GLP-1 receptor agonist, has been clinically approved
for treatment of type 2 diabetes mellitus and is available in subcutaneous and oral dosage …

Ligand-activated nuclear receptors, including peroxisome proliferator-activated receptor
alpha (PPARα), pregnane X receptor, and constitutive androstane receptor, were first …

Colorectal cancer (CRC) is one of the most commonly diagnosed cancers, and it is
characterized by genetic and epigenetic alterations, as well as by inflammatory cell …

Non-alcoholic fatty liver disease (NAFLD) is a major chronic liver disease that can lead to
liver cirrhosis, liver cancer, and ultimately death. NAFLD is pathologically classified as non …

Objectives Vitamin E is often used in the treatment of nonalcoholic fatty liver disease
(NAFLD), including nonalcoholic steatohepatitis (NASH); however, the magnitude of …

Metabolic syndrome (MetS) is characterized by an association of cardiovascular and
diabetes mellitus type 2 risk factors. Although the definition of MetS slightly differs depending …

Nonalcoholic fatty liver disease (NAFLD) is a major cause of chronic liver disease in the
Western population. We investigated the association of nonalcoholic fatty liver disease …

Non-alcoholic fatty liver disease (NAFLD) can gradually develop into hepatic failure, and
early diagnosis is crucial to improve treatment efficiency. The occurrence of NAFLD is …

Objective. Nonalcoholic fatty liver disease (NAFLD) is the most prevalent chronic liver
disease in the world. The pathogenesis of NAFLD is complex and multifactorial. Clinical …